New hope for hard-to-treat myeloma? early trial launches for QI-019B
NCT ID NCT07539233
First seen Apr 24, 2026 · Last updated May 13, 2026 · Updated 4 times
Summary
This early-stage study tests a new drug called QI-019B in 24 adults with multiple myeloma that has returned or not responded to at least two prior treatments. The main goal is to check safety and side effects, while also seeing if the drug can shrink the cancer. It is a single-center, open-label trial, meaning everyone gets the drug and knows what they are taking.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.